

(51) International Patent Classification:
A61P 25/28 (2006.01)

(21) International Application Number:

PCT/US2012/064722

(22) International Filing Date:

12 November 2012 (12.11.2012)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/558,430	10 November 2011 (10.11.2011)	US
61/589,809	23 January 2012 (23.01.2012)	US
13/582,308	31 August 2012 (31.08.2012)	US

(71) Applicants: **CANGENE U.S., INCORPORATED** [US/CA]; 155 Innovation Drive, Winnipeg, MB R3T 5Y3 (CA). **THE UNIVERSITY OF BRITISH COLUMBIA** [CA/CA]; 103-6190 Agronomy Road, Vancouver, BC V6T 1Z3 (CA).

(72) Inventors: **CASHMAN, Neil, R.**; 3793 West King Edward Avenue, Ncouver, BC V6S 1M8 (CA). **MCCLARTY, Grant**; 276 Chalfont Road, Winnipeg, MB R3R 0R3 (CA).

(74) Agent: **DAVITZ, Michael, A.**; Fahmi, Sellers & Embert, 84 W. Santa Clara St., Suite 550, San Jose, CA 95113 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) Title: COMPOSITIONS AND METHODS FOR TREATING ALZHEIMER'S DISEASE




Figure 1

(57) Abstract: The present disclosure provides for a hyperimmune preparation comprising human polyclonal antibodies or fragments thereof specific to a cyclic peptide having an amino acid sequence comprising SNK. The cyclic peptide may comprise an amino acid sequence GSNK (SEQ ID NO: 1), SNKG (SEQ ID NO: 2), GSNKG (SEQ ID NO: 3), CSNKG (SEQ ID NO: 4), CG-SNKG (SEQ ID NO: 5), CGSNKGG (SEQ ID NO: 6), or CCGSNKGC (SEQ ID NO: 7). The antibodies in the hyperimmune preparation may have a titer ranging from about 200 to about 400 mean fluorescence intensity (MFI). In one embodiment, greater than about 80% of the antibodies in the hyperimmune preparation are IgG. The fragments of the antibodies are Fab, F(ab')₂, scFv, disulfide linked Fv, or mixtures thereof.



Published:

— with international search report (Art. 21(3))

— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))